App-Quantinova.ai

Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience

Sibel Naycı - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Nintedanib

Safety and Tolerability of Combination Therapy with Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis: A Multicenter, Retrospective, Observational Study in Japan

Shu Hisata - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis

Ying Qiu - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience

Anna Agnese Stanziola - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Association between antifibrotic medications and pneumothorax or pneumomediastinum in patients with idiopathic pulmonary fibrosis

Taisuke Akamatsu - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Results of antifibrotic drugs in the treatment of idiopathic pulmonary fibrosis. A real life study

Jacinto Hernandez Borge - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Idiopathic pulmonary fibrosis (IPF: the patient journey

Vincent Cottin - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Distinctive polarization of circulating classical monocytes between idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial pneumonia

Masahiro Yamashita - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Temporal subtraction of serial CT scans for visualisation and quantification of disease progression in Idiopathic Pulmonary Fibrosis

Hoen-oh Shin - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Association between MUC5B rs35705950 genotype and response to antifibrotic treatment in patients with Idiopathic Pulmonary Fibrosis (IPF

Elisabetta Cocconcelli - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Relationship Between Air Pollution in Madrid and the Mortality of Idiopathic Pulmonary Fibrosis

Pablo Mariscal Aguilar - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Association between influenza vaccination and the occurrence of acute exacerbation in idiopathic pulmonary fibrosis

Lucile Sese - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Difference between pathogenic and inhibitory bacterial florae is associated with acute exacerbation of idiopathic pulmonary fibrosis

Shinichiro Ohshimo - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Clinical burden of idiopathic pulmonary fibrosis (IPF: physician and patient perception

Francesco Bonella - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Is Pulmonary Rehabilitation A Savior In Idiopathic Pulmonary Fibrosis?

Seher Satar - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Feasibility of a cardiopulmonary exercise test (CPET derived high-intensity interval training programme (HIIT in idiopathic pulmonary fibrosis (IPF

Tim Wallis - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Idiopathic pulmonary fibrosis (IPF: observations from a Phase 2 trial of GLPG1205 (PINTA

Irina Ruxandra Strambu - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

GLPG1205

Gender differences in idiopathic pulmonary fibrosis: are men and women equal or not?

Lucile Sese - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Single-arm observational study of a mobile app + home spirometry in idiopathic pulmonary fibrosis

Lynn Fox - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Correlation between physical activity and prognostic markers in patients with idiopathic pulmonary fibrosis

Merve Sinem Oguz - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Filters

914 Abstracts